Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Embolism × Rivaroxaban × Clear all

Status

Active not recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Neoplasms 15 Venous Thromboembolism 13 Venous Thrombosis 5 Treatment of Venous Thromboembolism in Cancer Patients 3 Upper Extremity Deep Vein Thrombosis 2 Thrombosis 2 Pulmonary Embolism 2 Lung Neoplasms 2 Colonic Neoplasms 2 Urologic Neoplasms 1 Urogenital Neoplasms 1 Thromboembolism 1 Recurrence 1 Prostatic Neoplasms 1 Prevention of Venous Thromboembolism 1 Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery 1 Myeloproliferative Disorders 1 Multiple Myeloma 1 Inflammation 1 Immune System Diseases 1 Hemorrhage 1 Glioma 1 Embolism 1 Dyskinesias 1 Cardiovascular Diseases 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1

Interventions

edoxaban 1 apixaban 1 Warfarin 1 Rivaroxaban 1 Heparin, Low-Molecular-Weight 1 Dalteparin 1 Dabigatran 1 4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04618913 2026-03-12

VICTORIE

Pfizer

Active not recruiting

Classical hematology

Embolism, Neoplasms, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon ⚡